An Observational Study on the Management of COVID-19 Patients in Limited-Resource Hospitals
PDF

Keywords

COVID-19
Limited-resource hospitals
COVID-19 laboratory tests
Comorbidities

DOI

10.26689/jcnr.v6i3.3852

Abstract

Background: The purpose of this study was to evaluate the effectiveness of limited-resource hospitals in managing mild and moderate hospitalized cases of COVID-19 with comorbidities and in preventing their progression to severe illness. Methods: Data were obtained from 88 moderate COVID-19 patients with comorbidities who were admitted to limited-resource hospitals. The data were classified into several parts: comorbidities, chronic medication before hospital admission, symptoms of COVID-19 before and during hospitalization, clinical features, laboratory findings on hospital admission, complications during hospitalization, as well as worst laboratory values during hospitalization, hospital stay, and outcomes. The clinical features, laboratory results, type of oxygen therapy used, and the final treatment outcome were all evaluated to assess for any potential relationship. Results: All patients were alive upon discharge. Before admission, the majority of patients (60.2%) received COVID-19 treatment, and the average hospital stay was 12 days. The most common symptoms were fever (88.7%), cough (95.5%), shortness of breath (90.9%), myalgia (84.1%), confusion (63.6%), headache (62.5%), sore throat (88.7%), rhinorrhea (17%), chest pain (58%), diarrhea (19.3%), nausea and vomiting (38.6%), anosmia (62.5%), as well as dysgeusia (64.8%). Based on chest radiograph or computed tomography (CT) scan, 9.1% of the patients had unilateral pneumonia, 90.9% had bilateral pneumonia, and 96.6% had multiple mottling and ground-glass opacity. Age was found associated with a significant increase in headache (p = 0.005), rhinorrhea (p = 0.013), chest pain (p = 0.007), and the need for positive airway pressure (p = 0.008). Between pre- and post-hospital admissions, there was a significant increase in lactate dehydrogenase and ferritin but a decrease in platelet, D-dimer, hemoglobin, lymphocytes, neutrophils, and total leucocyte count (p < 0.001). There was a significant association between hospital stay and D-dimer level (p = 0.05). Conclusion: Limited-resource hospitals in Egypt were efficient in managing mild and moderate hospitalized cases of COVID-19 with comorbidities. Many of these cases did not escalate to severe illness and were all alive upon discharge. Early management of COVID-19 tends to delay the disease progression to severe illness and improves patients’ chances of survival. Treating COVID-19 or using oxygen therapy at home can also delay the need for hospitalization in mild or moderate cases.

References

Dar M, Swamy L, Gavin D, et al., 2020, Mechanical Ventilation Supply and Options for the COVID-19 Pandemic: Leveraging All Available Resources for a Limited Resource in a Crisis. Annals of the American Thoracic Society, 18(3): 1-28.

Siow WT, Liew MF, Shrestha BR, et al., 2020, Managing COVID-19 in Resource-Limited Settings: Critical Care Considerations. Critical Care, 24: 167.

Yang X, Yu Y, Xu J, et al., 2020, Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. The Lancet Respiratory Medicine, 8(5): 475-481.

Wallis LA, 2020, African Federation for Emergency Medicine Resources for Managing COVID-19 in Low Resourced Settings. African Journal of Emergency Medicine, 10(2): 49.

Yang J, Zheng Y, Gou X, et al., 2020, Prevalence of Co-Morbidities and Its Effects in Coronavirus Disease 2019 Patient: A Systematic Review and Meta-Analysis. International Journal of Infectious Diseases, 94: 91-95.

Saeed H, Osama H, Madney YM, et al., 2020, COVID-19; Current Situation and Recommended Interventions. International Journal of Clinical Practice, 75(5): e13886.

Montoya A, Jenq G, Mills JP, et al., 2020, Partnering with Local Hospitals and Public Health to Manage COVID?19 Outbreaks in Nursing Homes. Journal of the American Geriatrics Society, 69(1): 30-36.

Guan W, Ni Z, Hu Y, et al., 2020, Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 382(18): 1708-1720.

Mo P, Xing Y, Xiao Y, et al., 2020, Clinical Characteristics of Refractory COVID-19 Pneumonia in Wuhan, China. Clinical Infectious Diseases, 73(11): e4208-e4213.

Du Y, Tu L, Zhu P, et al., 2020, Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. American Journal of Respiratory and Critical Care Medicine, 201(11): 1372-1379.

Deng Y, Liu W, Liu K, et al., 2020, Clinical Characteristics of Fatal and Recovered Cases of Coronavirus Disease 2019 in Wuhan, China: A Retrospective Study. Chinese Medical Journal, 133(11): 1261-1267.

Elgendy MO, Abd Elmawla MN, Abdel Hamied AM, et al., 2020, COVID?19 Patients and Contacted Person Awareness About Home Quarantine Instructions. International Journal of Clinical Practice, 75(4): e13810.

Huang C, Wang Y, Li X, et al., 2020, Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395(10223): 497-506.

Chen N, Zhou M, Dong X, et al., 2020, Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet, 395(10223): 507-513.

Wang T, Du Z, Zhu F, et al., 2020, Comorbidities and Multi-Organ Injuries in the Treatment of COVID-19. The Lancet, 395(10228): e52.

Long L, Wu L, Chen L, et al., 2021, Effect of Early Oxygen Therapy and Antiviral Treatment on Disease Progression in Patients with COVID-19: A Retrospective Study of Medical Charts in China. PLoS Neglected Tropical Diseases, 15(1): e0009051.

Sayed AM, Khalaf AM, Abdelrahim MEA, et al., 2020, Repurposing of Some Anti?Infective Drugs for COVID?19 Treatment: A Surveillance Study Supported by an In Silico Investigation. International Journal of Clinical Practice, 75(4): e13877.

Elgendy MO, El-Gendy AO, Abdelrahim ME, 2020, Public Awareness in Egypt About COVID-19 Spread in the Early Phase of the Pandemic. Patient Education and Counseling, 103(12): 2598-2601.

Pan L, Mu M, Yang P, et al., 2020, Clinical Characteristics of COVID-19 Patients with Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. The American Journal of Gastroenterology, 115(5): 766-773.

Peng J, Qi D, Yuan G, et al., 2020, Diagnostic Value of Peripheral Hematologic Markers for Coronavirus Disease 2019 (COVID?19): A Multicenter, Cross?Sectional Study. Journal of Clinical Laboratory Analysis, 34(10): e23475.

Abobaker A, 2020, Reply: Iron Chelation May Harm Patients with COVID-19. European Journal of Clinical Pharmacology, 77(4): 267-268.

Samrah SM, Al-Mistarehi AHW, Ibnian AM, et al., 2020, COVID-19 Outbreak in Jordan: Epidemiological Features, Clinical Characteristics, and Laboratory Findings. Annals of Medicine and Surgery, 57: 103-108.

Tang N, Li D, Wang X, et al., 2020, Abnormal Coagulation Parameters are Associated with Poor Prognosis in Patients with Novel Coronavirus Pneumonia. Journal of Thrombosis and Haemostasis, 18(4): 844-847.

Ferrari D, Motta A, Strollo M, et al., 2020, Routine Blood Tests as a Potential Diagnostic Tool for COVID-19. Clinical Chemistry and Laboratory Medicine (CCLM), 58(7): 1095-1099.

Jurisic V, Radenkovic S, Konjevic G, 2015, The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects. Advances in Cancer Biomarkers, 867: 115-24